Inovio Pharmaceuticals (INO) Common Equity (2010 - 2026)

Inovio Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting $4.4 million for Q2 2026.

• In Q2 2026, Common Equity fell 84.68% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (down 84.68% YoY), while the FY2025 annual figure was $24.1 million, down 64.82% from the prior year.
• Common Equity came in at $4.4 million for Q2 2026 at Inovio Pharmaceuticals, down from $6.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $355.1 million in Q1 2022 to a low of -$7.7 million in Q3 2025.
• Average Common Equity over 5 years is $122.5 million, with a median of $95.6 million recorded in 2024.
• Year-over-year, Common Equity plunged 38.95% in 2022 and tumbled 110.5% in 2025.
• Over 5 years, Common Equity stood at $222.4 million in 2022, then tumbled by 47.23% to $117.3 million in 2023, then slumped by 41.62% to $68.5 million in 2024, then tumbled by 64.82% to $24.1 million in 2025, then sank by 81.86% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $4.4 million in Q2 2026, $6.1 million in Q1 2026, and $24.1 million in Q4 2025.